He is a Howard Hughes Medical Institute investigator, a member of the National Academy of Sciences and the American Academy of Sciences. Janeway Professor of Pediatrics, HMS, Scientific Director, CBRI Institute for Biomedical Research.Fred Alt received a PhD from the Department of Biological Sciences at Stanford University. Alt is also Investigator, Howard Hughes Medical Inst., Charles A. Alt, Ph.D., member of the National Academy of Sciences, Professor, Harvard Medical Schoolĭr. Frederick Alt Harvard Medical School, Boston, MAįrederick W.Cory Abate-Shen Columbia University, New York, NYĬory Abate-Shen, PhD, Professor, Director of Research, Department of Pathology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University, NY.Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases. His research interests range from molecular and cellular biology to clinical investigations. He has served as Associate Editor ofĬell Cycle.

Blagosklonny is the author of over 250 articles in peer-reviewed journals. Blagosklonny, M.D., Ph.D., Professor, Roswell Park Comprehensive Cancer Center, Buffalo, NYĭr. Blagosklonny Roswell Park Comprehensive Cancer Center, Buffalo, NY His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc and Tartis, Inc. His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. Gudkov, PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Comprehensive Cancer Center, Buffalo, NY Gudkov Roswell Park Comprehensive Cancer Center, Buffalo, NYĪndrei V. 2016 Jul 19 7(29):45144-45157.ĭynamic changes during the treatment of pancreatic cancer.Īndrei V. Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR. Levine:ĭLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers. Featured articles by DR Lowy, the acting director of the NCI (2015-2017), and A.

Ipf omaha